2024
Multi-center retrospective review of vitiligo-like lesions in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors
Bang A, Fay C, LeBoeuf N, Etaee F, Leventhal J, Sibaud V, Arbesman J, Wang J, Kwong B. Multi-center retrospective review of vitiligo-like lesions in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors. Breast Cancer Research And Treatment 2024, 204: 643-647. PMID: 38224427, DOI: 10.1007/s10549-023-07217-2.Peer-Reviewed Original ResearchVitiligo-like lesionsProgression-free survivalSurvival benefitMedian progression-free survivalAssociated with survival benefitSkin-directed therapiesMetastatic breast cancerSun-exposed areasPotential treatment optionCyclin-dependent kinase 4ConclusionClinical characteristicsMild repigmentationRuxolitinib creamTopical ruxolitinibMethodsRetrospective reviewResultsMedian ageClinical characteristicsCase reportTreatment optionsBreast cancerKinase inhibitorsCDK4/6iInternational cohortPatientsQuality of life
2023
Recognition and Treatment of Wounds in Persons Using Xylazine: A Case Report From New Haven, Connecticut
Dowton A, Doernberg M, Heiman E, Barelli P, Golden M, Wang H, Leventhal J, Morford K, Sue K. Recognition and Treatment of Wounds in Persons Using Xylazine: A Case Report From New Haven, Connecticut. Journal Of Addiction Medicine 2023, 17: 739-741. PMID: 37934550, DOI: 10.1097/adm.0000000000001198.Peer-Reviewed Original ResearchConceptsOpioid use disorderUse disordersDrug useCase report presentsIndex of suspicionInjection drug useDrug supplyCare management strategiesHarm reduction strategiesOverdose presentationsCutaneous manifestationsWithdrawal syndromeClinical complicationsCase reportIntravenous useWound carePatientsTreatment of woundsInfectious diseasesChronic woundsXylazineSkin woundsWoundsMore reportingDiagnosis
2021
Subcutaneous Fat Necrosis During Nivolumab Therapy for Metastatic Melanoma
Pach J, Olamiju B, Weiss S, Damsky W, Leventhal J. Subcutaneous Fat Necrosis During Nivolumab Therapy for Metastatic Melanoma. JAMA Dermatology 2021, 157: 468-469. PMID: 33688919, DOI: 10.1001/jamadermatol.2021.0058.Peer-Reviewed Original Research